MDTMedtronic plc

NYSE medtronic.com


$ 82.29 $ 0.91 (1.12 %)    

Friday, 24-May-2024 15:59:57 EDT
QQQ $ 454.82 $ 4.29 (0.95 %)
DIA $ 398.57 $ -0.02 (-0.01 %)
SPY $ 530.36 $ 3.48 (0.66 %)
TLT $ 91.26 $ 0.27 (0.3 %)
GLD $ 225.37 $ 0.20 (0.09 %)
$ 82.29
$ 81.19
$ 0.00 x 0
$ 0.00 x 0
$ 80.93 - $ 82.33
$ 67.71 - $ 88.75
8,732,273
na
109.27B
$ 0.93
$ 26.00
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-27-2024 01-26-2024 10-Q
2 11-30-2023 10-27-2023 10-Q
3 08-31-2023 07-28-2023 10-Q
4 06-22-2023 04-28-2023 10-K
5 03-01-2023 01-27-2023 10-Q
6 12-01-2022 10-28-2022 10-Q
7 09-01-2022 07-29-2022 10-Q
8 06-23-2022 04-29-2022 10-K
9 03-03-2022 01-28-2022 10-Q
10 12-02-2021 10-29-2021 10-Q
11 09-02-2021 07-30-2021 10-Q
12 06-25-2021 04-30-2021 10-K
13 03-05-2021 01-29-2021 10-Q
14 12-03-2020 10-30-2020 10-Q
15 09-03-2020 07-31-2020 10-Q
16 06-19-2020 04-24-2020 10-K
17 02-28-2020 01-24-2020 10-Q
18 12-03-2019 10-25-2019 10-Q
19 08-30-2019 07-26-2019 10-Q
20 06-21-2019 04-26-2019 10-K
21 03-01-2019 01-25-2019 10-Q
22 11-29-2018 10-26-2018 10-Q
23 08-31-2018 07-27-2018 10-Q
24 06-22-2018 04-27-2018 10-K
25 03-02-2018 01-26-2018 10-Q
26 12-04-2017 10-27-2017 10-Q
27 09-01-2017 07-28-2017 10-Q
28 06-27-2017 04-28-2017 10-K
29 03-03-2017 01-27-2017 10-Q
30 12-05-2016 10-28-2016 10-Q
31 09-07-2016 07-29-2016 10-Q
32 06-28-2016 04-29-2016 10-K
33 03-09-2016 01-29-2016 10-Q
34 12-09-2015 10-30-2015 10-Q
35 09-09-2015 07-31-2015 10-Q
36 06-23-2015 04-24-2015 10-K
37 02-27-2015 01-23-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wells-fargo-maintains-overweight-on-medtronic-raises-price-target-to-105

Wells Fargo analyst Larry Biegelsen maintains Medtronic (NYSE:MDT) with a Overweight and raises the price target from $102 t...

 rbc-capital-reiterates-sector-perform-on-medtronic-maintains-92-price-target

RBC Capital analyst Shagun Singh reiterates Medtronic (NYSE:MDT) with a Sector Perform and maintains $92 price target.

 ubs-maintains-sell-on-medtronic-raises-price-target-to-76

UBS analyst Matthew Taylor maintains Medtronic (NYSE:MDT) with a Sell and raises the price target from $75 to $76.

 truist-securities-maintains-hold-on-medtronic-lowers-price-target-to-88

Truist Securities analyst Richard Newitter maintains Medtronic (NYSE:MDT) with a Hold and lowers the price target from $90 t...

 needham-reiterates-hold-on-medtronic

Needham analyst Mike Matson reiterates Medtronic (NYSE:MDT) with a Hold.

 nvidias-10-leap-propels-tech-indexes-to-record-highs-blue-chips-small-caps-slip-whats-driving-markets-thursday

Strong earnings and revenue guidance from Nvidia sparked a tech stock surge, with Nasdaq 100 and S&P 500 hitting record highs.

 medtronics-q4-earnings-medical-device-giant-clocks-strong-sales-from-neurology-devices-hikes-dividend

Medtronic reported Q4 2024 sales of $8.59 billion, with 0.5% reported and 5.4% organic revenue growth. Dividend increased to $0...

 wall-street-braces-for-strong-open-on-nvidia-cheer-but-traders-wary-of-key-data-why-this-analyst-sees-more-market-bullishness-near-term

Major U.S.

 medtronics-heart-catheter-achieves-safety-and-efficacy-goals-in-patients-with-irregular-heartbeat

Medtronic's SPHERE Per-AF study results reveal the Sphere-9 Catheter's superior safety and efficacy in treating persist...

 medtronic-affera-mapping-and-ablation-system-with-sphere-9-catheter-achieves-endpoints-for-safety-and-efficacy

The Sphere-9 Catheter demonstrated a positive safety profile with an excellent primary safety endpoint rate of 1.4% (1.0% for t...

 medtronic-presented-late-breaking-data-showing-performance-of-its-omniasecure-defibrillation-lead-met-its-primary-safety-and-effectiveness-endpoints-exceeding-prespecified-performance-goals-in-the-global-leadr-pivotal-trial

Global LEADR clinical trial meets safety and effectiveness objectives; results presented at Heart Rhythm 2024 and simultaneousl...

 will-insulets-monopoly-crumble-appellate-court-ruling-signals-shift-in-automated-insulin-delivery-systems-market

Latest on Insulet and its legal battle with EOFlow. Understand the impact of the appellate court's decision on market dynam...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION